SANA BIOTECHNOLOGY INC. - COMMON STOCK

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

05 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

11 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

01 Dec 2023 16:05:35 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at November and December 2023 Investor Conferences

21 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

17 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

09 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

08 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

02 Nov 2023 09:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

10 Oct 2023 16:15:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at September 2023 Investor Conferences

30 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

03 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

16 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at June 2023 Investor Conferences

31 May 2023 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

08 May 2023 16:35:00 By Nasdaq GlobeNewswire

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

08 May 2023 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at May 2023 Investor Conferences

03 May 2023 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

02 May 2023 16:30:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Host Research & Development Day

24 Apr 2023 16:06:02 By Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

19 Apr 2023 16:05:00 By Nasdaq GlobeNewswire